Esbriet is a prescription medicine
for the treatment of IPF. IPF is
different from other interstitial
lung diseases (ILD), or diseases
that cause inflammation and scarring
of the lungs. Esbriet is
specifically studied and approved
for use in IPF, which is a certain
type of ILD.
Although lung function that is lost
cannot be restored, treatment may
help maintain more of your lung
function by slowing the progression
of the disease.
In the clinical studies, the effect of Esbriet on lung function (how well the lungs work) was measured by forced vital capacity (FVC). FVC measures the amount of air you can exhale with force after you inhale as deeply as possible.
IPF is progressive, so slowing its decline can be an important goal of treatment
Starting and staying on Esbriet treatment as prescribed by your doctor can be an important way to help preserve more of the lung function you have today by slowing disease progression
Esbriet has been shown to preserve lung function. Therefore, once you begin taking Esbriet, you may not “feel” different because Esbriet does not treat the symptoms of IPF and does not reverse the scarring in your lungs
The link you have selected will take you away from this site to one that is not owned or controlled by Legacy Pharma Inc. SEZC. Legacy Pharma Inc. SEZC makes no representation as to the accuracy of the information contained on sites we do not own or control. Legacy Pharma Inc. SEZC does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.